Terms: = Gastric cancer AND SLC34A2, ENSG00000157765, O95436, NPTIIb, NAPI-IIb, NAPI-3B, FLJ90534, 10568 AND Treatment
2 results:
1. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract] [Full Text] [Related]
2. Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of slc34a2 and Raf/MEK/ERK pathway.
Zhang JX; Xu Y; Gao Y; Chen C; Zheng ZS; Yun M; Weng HW; Xie D; Ye S
Mol Cancer; 2017 Jan; 16(1):18. PubMed ID: 28114937
[TBL] [Abstract] [Full Text] [Related]